Selective decontamination of the digestive tract (SDD) involves administering nonabsorbable oral antibiotics to hospitalized ... (daily oral polymyxin E, tobramycin, and amphotericin B) for ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

Clinical question: Is there a mortality difference between early transition to oral antibiotics versus prolonged intravenous antibiotics in uncomplicated gram-negative bacteremia? Background: Although ...

The median duration of antibiotic treatment was 57 days (8.1 weeks; IQR 44–83 days). Switch to an oral antibiotic regimen was performed in 72% of patients after a median intravenous therapy of ...

FDA accepted GSK's gepotidacin application for uUTI treatment with a PDUFA date set for March 26, 2025. Gepotidacin showed superior efficacy over nitrofurantoin in EAGLE-3 trial with a 58.5% ...

Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care.

The FDA on Friday signed off on Iterum Therapeutics’ oral antibiotic sulopenem etzadroxil and probenecid, which will now be marketed as Orlynvah, for the treatment of uncomplicated urinary tract ...

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and probenecid) oral sulopenem) for the treatment of uncomplicated urinary tract ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...